Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's...

Area of Science:

• Pediatric Oncology
• Cancer Research
• Clinical Trials

Background:

• Stage IV-S neuroblastoma is a metastatic form of cancer in infants.
• While often associated with spontaneous regression and good survival rates, a subset of infants face early mortality due to complications.
• Understanding prognostic factors is crucial for optimizing treatment strategies.

Purpose of the Study:

• To evaluate the outcomes and identify prognostic factors in infants diagnosed with stage IV-S neuroblastoma.
• To assess the effectiveness of a treatment approach involving only supportive care or low-dose cytotoxic therapy for symptomatic cases.

Main Methods:

• Prospective study of 80 eligible infants with stage IV-S neuroblastoma.
• Treatment arms included supportive care or cyclophosphamide with or without hepatic radiation.
• Centralized review of staging, MYCN gene copy number, Shimada histopathologic classification, serum ferritin, and bone marrow immunocytology.

Main Results:

• High concordance between Stage IV-S and International Neuroblastoma Staging System stage 4S.
• Favorable histopathology and absence of MYCN amplification were common.
• 5-year event-free survival was 86%, and overall survival was 92%.
• Infants receiving only supportive care had a 100% survival rate versus 81% for those requiring cytotoxic therapy (P=.005).
• Deaths primarily occurred in infants under 2 months with extensive abdominal disease and respiratory compromise or DIC.
• Age ≤3 months at diagnosis was significant for EFS, and favorable Shimada classification predicted improved survival.

Conclusions:

• Infants with stage IV-S neuroblastoma exhibit favorable biology and excellent survival outcomes with minimal therapeutic intervention.
• Early and potentially more intensive treatment may be beneficial for infants diagnosed under 2 months with rapidly progressing abdominal disease.